Adamis Pharma -61% on FDA’s Zimhi rejection

The FDA rejects Adamis Pharmaceuticals (NASDAQ:ADMP) opioid overdose treatment.

In a letter to the company, the FDA cited concerns about Zimhi’s chemistry and manufacturing but not the safety or efficacy.

Adamis plans to expand on the chemistry, manufacturing, and controls testing to satisfy the items in the FDA’s Complete Response Letter.

ADMP shares plunge 61% pre-market to $0.49.

https://seekingalpha.com/news/3521768-adamis-pharma-minus-61-percent-fdas-zimhi-rejection